OUR NEW PROFILE IS:  (NASDAQ: SILO)

Recently SILO announced its topically administered Ketamine reached a positive end point in an animal study  

SILO uplisted to Nasdaq on September 27 and completed a $5.7 million public offering

SILO has $4.6 million in the treasury as of March 31

SILO has a float of just 2.67 Million

_______________________

Hello Everyone,

Turn your attention to SILO right away for Monday’s session. 

Silo Pharma Inc (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Silo is committed to developing innovative solutions to address conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. 

Intellectual property: To date, Silo has filed 4 provisional patent applications related to the use of the central nervous system-homing peptides covered by the UMB Option Agreement to deliver certain compounds, including a nonsteroidal anti-inflammatory drug and/or psilocybin, for the treatment of arthritis, central nervous system diseases, neuroinflammatory diseases as well as cancer. In addition, pursuant to the Company’s acquisition of NFID, Silo acquired three trademarks related to the NFID brand. 

SILO is Harnessing the Power of Psychedelics to Deliver Breakthrough Medical Solutions

Silo has entered into research agreements and partnerships with multiple leading medical universities, including: 

• A sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease; 
• A scientific research agreement with the University of California San Francisco (UCSF) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation; 
• An exclusive license agreement with the University of Maryland, Baltimore (UMB) to explore a patent focused on enhanced targeting of therapeutic agents to the central nervous system; 
• A second exclusive option agreement with UMB to license a joint-homing peptide targeted at arthritis-inflamed joints; and 
• An agreement with Columbia University granting it an option to license two distinct assets currently under development, one focused on Alzheimer’s disease and a second focused on PTSD and stress. 

Psilocybin is considered a serotonergic hallucinogen and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising, and Silo Pharma believes there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders. While classified as a Schedule I substance under the Controlled Substances Act (“CSA”), there is an accumulating body of evidence that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug Administration (“FDA”) and U.S. Drug Enforcement Agency (“DEA”) have permitted the use of psilocybin in clinical studies for the treatment of a range of psychiatric conditions. 

The potential of psilocybin therapy in mental health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated and has the potential to treat depression when administered with psychological support. 

Silo Pharma has engaged in discussions with a number of world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board that is intended to help advise management regarding potential acquisition and development of products. 

In addition, as more fully described below, Silo Pharma has entered into a license agreement with the University of Baltimore, Maryland, and has entered into a joint venture with Zylo Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for targeted delivery of potential novel treatments. In addition, Silo Pharma has recently entered into a sponsored research agreement with Columbia University pursuant to which it has been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds. 

Silo Pharma plans to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus on this new line of business. 

SILO Pipeline:

.Silo Pharma believes in following the science to identify the best application for a therapeutic rather by targeting indications with the biggest need and selecting the best route of delivery for patients. Our current assets have shown promise in a range of illnesses and diseases, including Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

SILO Pharma’s Primary Asset Has Extraordinary Potential

SPC-14 Targeting Alzheimer’s 

505(b)(2) Pathway / preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University / SPC-14 has shown reduced hyponeophagia in animal studies / SPC-14 may reduce behavioral despair / Silo has licensed technology with Columbia and has recently entered into a scientific research agreement with Dr. Denny’s lab 

Market Opportunity – Alzheimer’s Disease / 6.5 million Americans suffer from Alzheimer’s and related diseases /  ~1 in 9 Americans 65+ have Alzheimer’s v U.S. market for relevant drugs expected to reach $5 billion by 2027 

Technology – Licensed from Columbia University / SPC-14 is a novel drug combining two approved therapeutics / SPC-14 targets NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms in Alzheimers.

SPC-15 Targeted prophylactic treatment—Stress-induced affective disorders  

Sponsored Research Agreement with Columbia University Prevention of stress-induced affective disorders / Increasing stress resilience in military, first responders, and other populations at high risk of PTSD / Predicting the level of severity or progression such disorders / Molecular targets for use in drug discovery of innovative treatments. 

Market Opportunity – Targeted prophylactic treatment—Stress-induced affective disorders / 26% of Americans 18+ suffer from anxiety, PTSD and other disorders / This number has escalated post-COVID-19 / U.S. market for relevant drugs expected to reach $13 billion by 2027 

Technology – Metabolomic biomarkers predict response to pharmacological treatments / Utilizes ketamine compositions as a method for treatment and prevention.

SP-26 Time-Released Psilocybin, Ketamine 

Deliver Ketamine or Psilocybin in a time-released manner / Will time-release diminish the hallucinogenic effects of these psychedelics / Pre clinical study underway shows Z-pod can hold and distribute Ketamine / Efficacy study in animals underway. 

Market Opportunity – Time-Released Psilocybin, Ketamine / Multiple Indications 

Technology – Joint Venture with Zylö Therapeutics, Inc. / Clinical development of psilocybin using ZTI’s Z-pod technology / Clinical development of Zylo’s sustained release topical delivery system.

SPU-16 CNS Homing Peptide 

May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord / May be used for diagnosing and monitoring MS / Decreases toxicity of existing therapeutics / Animal study results show much improved delivery of therapeutics and decreased toxicity. 

Market Opportunity – Multiple Sclerosis (MS) / There are approximately 400,000 Americans and 2.5 million people worldwide with MS / The most widespread disabling neurological condition of young adults / Global market for MS drugs expected to reach $25.3 billion by 202 

Technology- Licensed from University of Maryland Baltimore / Patent issued / Central nervous system-homing peptides / Use for investigation and treatment of MS and other neuroinflammatory pathology.

SPU-21 Arthritogenic Joint Homing Peptides Utilizing Psilocybin  

Identify markers of arthritic inflammation in joints / Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats / Peptide significantly inhibited arthritic progression in this animal model / Further studies are underway at UMB. 

Market Opportunity – Rheumatoid Arthritis (RA) / 1.3M U.S. adults suffer from RA / The most common autoimmune disease in U.S. / U.S. market for RA drugs expected to reach $63 billion by 2027 

Technology- Development plan to utilizing liposomal Homing Peptide to deliver targeted psilocybin / The ability of the peptides to target inflamed epithelium suggest they could be used to target drug delivery. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides can be used to treat autoimmune diseases, including but not limited to RA. 

How SILO Pharma’s Drug Delivery Platform Could Cause Massive Changes to How Diseases Are Treated 

Research has clearly shown that psychedelics – such as psilocybin – can offer significant benefits to those suffering from a number of disorders. But to date, the issue has been developing a psychedelic-based solution for these sufferers that was both practical and effective. Thanks to the potential of SILO Pharma’s unique drug delivery platform – developed in conjunction with university research – we could be on the verge of a significant breakthrough in treatment. SILO Pharma’s assets and research could be transformative to the well-being of patients worldwide…and disruptive to the healthcare industry as a whole. That alone sets Silo Pharma (OTC: SILO) apart from others in both the psychedelic and biopharma arenas. 

The research and development – based on the company’s unique homing peptide – could not only prove to be effective in the delivery of psychedelics…but also in delivery of traditional medication. That type of potential is deserving of attention from investors…but it’s also more difficult to project. A potential comparable stock that has demonstrated the potential for this company’s upside, however, does exist in the cannabis space. 

1) Double Play Investment Opportunity – Unlike many companies generating attention in the psychedelic space, SILO Pharma is focused on developing potential breakthroughs by combining traditional therapeutics with the power of psychedelic research.

2) Rapidly Growing Market – The market for psychedelics is projected to grow at a CAGR of 16.3% between now and 2027, when it is expected to reach $6.8 billion.

3) Potential Game-Changing Drug Delivery Platform – SILO Pharma’s potentially game-changing drug delivery platform may be used to treat a number of devastating diseases, including Rheumatoid Arthritis and Multiple Sclerosis and is likely to generate considerable attention from larger companies, making for attractive buyout potential.

4) Following a Proven Blueprint for Success – The company is following the same path forged in the cannabis sector by GW Pharma, and is working to combine the powerful healing benefits of psilocybin with its own unique drug delivery system in the hopes of developing a true game-changer that could ultimately prove disruptive to the entire healthcare industry.

5) Proven Leadership Team – Silo Pharma is led by an experienced team of business builders and researchers poised to make the company’s dream a reality. This team includes CEO Eric Weisblum, with over 20 years investing, building and managing businesses as well as an impressive scientific advisory board.

DISCLAIMER

*****We have been compensated for this email.